This patented technology is designed to enhance the light sensitivity of a multi-characteristic opsin developed by Nanoscope as a gene therapy.

AEYE Health is set to share the company’s FDA-cleared portable AI solution for autonomous diabetic retinopathy screening at several upcoming medical conferences in October. The device and the ...

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over inadequate screening and management, especially among Black and Hispanic youths.

This patented technology is designed to enhance the light sensitivity of a multi-characteristic opsin developed by Nanoscope as a gene therapy. Nanoscope Therapeutics Inc. has acquired a license for ...